RT Journal Article SR Electronic T1 Morbidity associated with Schistosoma mansoni infection in north-eastern Democratic Republic of the Congo JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.05.23.20108654 DO 10.1101/2020.05.23.20108654 A1 M Nigo, Maurice A1 Odermatt, Peter A1 Wully Nigo, David A1 Salieb-Beugelaar, Georgette B. A1 Battegay, Manuel A1 R Hunziker, Patrick YR 2020 UL http://medrxiv.org/content/early/2020/08/11/2020.05.23.20108654.abstract AB Background Controlling morbidity is the main target of schistosomiasis control. Yet only rarely do we assess morbidity linked to Schistosoma sp. infection. In the Democratic Republic of Congo (DRC), and particularly in the north-eastern Ituri province, morbidity associated with Schistosoma mansoni infection is unknown. For this reason, we aimed to assess intestinal and hepatosplenic morbidity associated with S. mansoni infection in Ituri province.Methods / Principal Findings In 2017, we conducted a cross-sectional study in 13 villages in Ituri province, DRC. S. mansoni infection was assessed with a Kato-Katz stool test (2 smears) and a point-of-care circulating cathodic antigen (POC-CCA) test in urine. A questionnaire was used to obtain demographic data and information about experienced intestinal morbidity. Each participant underwent an abdominal ultrasonography examination to diagnose hepatosplenic morbidity. Of the 586 study participants, 76.6% tested positive for S. mansoni. Intestinal morbidity, such as abdominal pain (52.7%), diarrhoea (23.4%) and blood in the stool (21.5%) in the previous two weeks, was very frequent. Hepatosplenic morbidity was demonstrated by abnormal liver parenchyma patterns (42.8%), hepatomegaly (26.5%), and splenomegaly (25.3%). Liver pathology (adjusted odds ratio [aOR] 1.20, 95% confidence interval [CI] 1.06–1.37, P=0.005) was positively and significantly associated with S. mansoni infection. Hepatomegaly (aOR 1.52, 95% confidence interval [CI] 0.99–2.32, P=0.053) and splenomegaly (aOR 1.12, 95% CI 0.73–1.72, P=0.619) were positively but not significantly associated with S. mansoni infection at the individual level. At the village level, S. mansoni prevalence was positively associated with the prevalence of hepatomegaly and splenomegaly. Higher S. mansoni infection intensities were associated with diarrhoea, blood in the stool, hepatomegaly, splenomegaly and with liver parenchyma, pathology patterns C, D, E and F. Four study participants were diagnosed with ascites and five reported hematemesis.Conclusions/Significance Our study documents a high burden of intestinal and hepatosplenic morbidity associated with S. mansoni infection status in Ituri province. The results call for targeted interventions to address both S. mansoni infection and related morbidity.Author Summary Schistosomiasis caused by Schistosoma mansoni is of great public health importance in sub-Saharan Africa. The World Health Organization (WHO) recommends that control efforts aim to reduce morbidity through large scale intervention programmes. However, intestinal and liver morbidity is rarely assessed in such control programmes. Hence, little is known about (i) the magnitude of the intestinal and liver morbidity burden in each community, or about (ii) the morbidity associated with S. mansoni infection, specifically. We conducted a (cross-sectional) study in which we assessed intestinal morbidity by questionnaire and liver morbidity by abdominal ultrasonography. Further, we determined the infection status of the study participants using standard diagnostic procedures (Kato-Katz technique and point-of-care cathodic circulating S. mansoni antigen [POC-CCA] test in urine). Among 586 study participants, six years and older, from 13 villages in Ituri province, DRC, we observed a high degree of intestinal (e.g. 23.4% with diarrhoea, 21.5% with blood in stool) and hepatosplenic morbidity (e.g. 42.8% with abnormal liver patterns C, D, E, and F, 26.5% with enlarged liver, 25.3% with enlarged spleen). S. mansoni infection was associated with liver and spleen enlargement. Likewise, S. mansoni infection intensity was linked to diarrhoea, to liver and spleen enlargement and to pathological changes in the liver parenchyma. At village level, we observed that the prevalence of enlarged liver and spleen among patients increased with the prevalence of S. mansoni infection. We conclude that the population of Ituri province carries an alarming burden of intestinal, liver and spleen morbidity associated with S. mansoni infection. Therefore, a comprehensive control programme to address this infection and disease burden is urgently required.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by private funds (Poverty Fund, Switzerland). The funders had no role in study design, data collection and data analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Swiss Ethical Commission (Ref. No. UBE 15/78) and by the University of Kisangani s Research Ethical Commission, (Ref No: CER/003/GEAK/2016). Research authorization was granted by the Nyankunde Higher Institute of Medical Techniques (Ref No 70/ISTM-N/SGAC/2017), Bunia, DRC. Permission for field work was obtained from the Ituri Provincial Health Division (Ref. 054/433/DPS/IT/06/2016 and Ref. 054/472/DPS/IT/06/2017) and from all relevant health districtsAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available.